{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:01:40Z","timestamp":1793977300343,"version":"4.8.0"},"reference-count":1037,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005485","name":"American College of Cardiology Foundation","doi-asserted-by":"publisher","award":["212-633-3820"],"award-info":[{"award-number":["212-633-3820"]}],"id":[{"id":"10.13039\/100005485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacc.2026.03.056","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:50:24Z","timestamp":1781034624000},"page":"e1889-e2007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"S","title":["2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome"],"prefix":"10.1016","volume":"87","author":[{"given":"Chiadi E.","family":"Ndumele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijah","family":"Breathett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoa L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine S.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Heffron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambar","family":"Kulshreshtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia C.","family":"Low Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Maga\u00f1a","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Neeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pagidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany M.","family":"Powell-Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutham","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosheen","family":"Reza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"St. Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bradley","family":"Starks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy W.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"VanWagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.03.056_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2025.05.009","article-title":"2025 AHA\/ACC statement on cost\/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Kazi","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jacc.2025.06.013","article-title":"2025 ACC\/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Otto","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2025.05.006","article-title":"Guidance for incorporating FDA processes into the ACC\/AHA clinical practice guideline methodology: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Jneid","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib4","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib5","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib6","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.03.056_bib7","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib10","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib12","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIR.0b013e3182285a81","article-title":"Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association","volume":"124","author":"Weintraub","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIR.0000000000000228","article-title":"Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association","volume":"132","author":"Havranek","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib15","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1161\/CIR.0000000000000582","volume":"137","author":"Brown","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib16","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib17","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib18","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1161\/CIR.0000000000000772","article-title":"Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association","volume":"141","author":"Mehta","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib19","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib20","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib21","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib22","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.03.056_bib23","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib24","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib25","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIR.0000000000001141","article-title":"Person-centered models for cardiovascular care: a review of the evidence: a scientific statement from the American Heart Association","volume":"148","author":"Rossi","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000134","article-title":"The role of primary care in achieving life's essential 8: a scientific statement from the American Heart Association","volume":"17","author":"Sterling","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib28","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1161\/CIR.0000000000001212","article-title":"Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: a scientific statement from the American Heart Association","volume":"149","author":"Lewey","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib29","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000001221","article-title":"Implementation of obesity science into clinical practice: a scientific statement from the American Heart Association","volume":"150","author":"Laddu","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib30","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC Scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib31","first-page":"e219","article-title":"Use of risk assessment to guide decision-making for blood pressure management in the primary prevention of cardiovascular disease: a scientific statement from the American Heart Association and American College of Cardiology","volume":"152","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib32","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1161\/CIR.0000000000001307","article-title":"Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association","volume":"151","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 Concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib2000","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001441","article-title":"Role of physical activity in obesity treatment and cardiometabolic health: a scientific statement from the American Heart Association","author":"Swift","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib34","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib35","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib36","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/CIRCULATIONAHA.122.060911","article-title":"Status of cardiovascular health in US adults and children using the American Heart Association's new \"Life's Essential 8\" metrics: prevalence estimates from the National Health and Nutrition Examination Survey (NHANES), 2013 through 2018","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000134","article-title":"The role of primary care in achieving life's essential 8: a scientific statement from the American Heart Association","volume":"17","author":"Sterling","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib38","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib39","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib40","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib41","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2026.03.056_bib42","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2026.03.056_bib43","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1161\/HYP.0000000000000215","article-title":"Ambulatory blood pressure monitoring in children and adolescents: 2022 update: a scientific statement from the American Heart Association","volume":"79","author":"Flynn","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2026.03.056_bib44","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib45","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib46","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehz239","article-title":"Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people","volume":"41","author":"Jaspers","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib47","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/S0140-6736(17)32250-X","article-title":"Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial","volume":"390","author":"Lindholt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib48","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa2208681","article-title":"Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial","volume":"387","author":"Lindholt","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib49","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcmg.2019.02.005","article-title":"Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC \u22651,000: results from the CAC consortium","volume":"13","author":"Peng","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.03.056_bib51","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcmg.2021.11.006","article-title":"Coronary artery calcium versus pooled cohort equations score for primary prevention guidance: randomized feasibility trial","volume":"15","author":"Muhlestein","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.03.056_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib53","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib54","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1001\/jama.2024.5596","article-title":"Prognostic value of cardiovascular biomarkers in the population","volume":"331","author":"Neumann","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib55","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ejhf.643","article-title":"Echocardiographic screening for non-ischaemic stage B heart failure in the community","volume":"18","author":"Yang","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/pubmed\/fdm045","article-title":"Reductions in cardiovascular risk in association with population screening: a 10-year longitudinal study","volume":"29","author":"McCluskey","year":"2007","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/j.jacc.2026.03.056_bib57","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib58","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102659","article-title":"Predicted risk, preclinical heart failure measures, and incident heart failure: the ARIC study","volume":"13","author":"Grant","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib60","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.119.043337","article-title":"Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC\/AHA high blood pressure guideline: a pooled cohort analysis","volume":"140","author":"Pandey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib62","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/CIRCULATIONAHA.119.043628","article-title":"Racial differences in malignant left ventricular hypertrophy and incidence of heart failure: a multicohort study","volume":"141","author":"Lewis","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.123.067530","article-title":"Optimal screening for predicting and preventing the risk of heart failure among adults with diabetes without atherosclerotic cardiovascular disease: a pooled cohort analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib64","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1161\/CIR.0000000000001307","article-title":"Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association","volume":"151","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib65","author":"Khan","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.jacc.2026.03.056_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00125-018-4753-5","article-title":"Trajectories of childhood BMI and adult diabetes: the Bogalusa Heart Study","volume":"62","author":"Zhang","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib67","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.106.648642","article-title":"Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study","volume":"115","author":"Lloyd-Jones","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib68","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.amepre.2023.01.007","article-title":"Screening for prediabetes and diabetes: clinical performance and implications for health equity","volume":"64","author":"O'Brien","year":"2023","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081444","article-title":"Occurrence of metabolic syndrome in midlife in relation to cardiovascular morbidity and all-cause mortality-lessons from a population-based matched cohort study with 27 years follow-up","volume":"14","author":"Lonnberg","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib70","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","article-title":"Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women","volume":"70","author":"Caleyachetty","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib71","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-8587(18)30137-2","article-title":"Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90,257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study","volume":"6","author":"Eckel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib72","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jacc.2007.09.038","article-title":"Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study","volume":"51","author":"Levitzky","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2011.03.025","article-title":"Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"58","author":"Yeboah","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib74","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1186\/s12889-025-21404-4","article-title":"Risk factors for progression to type 2 diabetes in prediabetes: a systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacc.2026.03.056_bib75","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archinte.161.7.996","article-title":"Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study","volume":"161","author":"He","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib76","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41467-017-02317-2","article-title":"Causal associations between risk factors and common diseases inferred from GWAS summary data","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2026.03.056_bib78","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2008-0222","article-title":"Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline","volume":"93","author":"Rosenzweig","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib79","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib80","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib82","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib83","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib84","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.2337\/dc22-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib85","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib86","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib87","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-134-1-200101020-00007","article-title":"Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II","volume":"134","author":"Stevens","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.02.390","article-title":"Association of waist circumference and body mass index with all-cause mortality in CKD: the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study","volume":"58","author":"Kramer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib90","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12882-021-02531-7","article-title":"The risk of chronic kidney disease in relation to anthropometric measures of obesity: a Swedish cohort study","volume":"22","author":"Memarian","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib91","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib92","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIR.0000000000001145","article-title":"Epidemiology of diabetes and atherosclerotic cardiovascular disease among Asian American adults: implications, management, and future directions: a scientific statement from the American Heart Association","volume":"148","author":"Kwan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/ejcn.2009.68","article-title":"Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature","volume":"64","author":"Huxley","year":"2010","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacc.2026.03.056_bib95","doi-asserted-by":"crossref","first-page":"827","DOI":"10.7326\/M14-2525","article-title":"Normal-weight central obesity: implications for total and cardiovascular mortality","volume":"163","author":"Sahakyan","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib96","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1467-789X.2011.00879.x","article-title":"Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk? evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies","volume":"12","author":"Czernichow","year":"2011","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib98","doi-asserted-by":"crossref","first-page":"I16","DOI":"10.1161\/01.HYP.17.1_Suppl.I16","article-title":"Implications of the INTERSALT study","volume":"17","author":"Stamler","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2026.03.056_bib99","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.2021.12531","article-title":"U. S. Preventive Services Task Force recommendation statement: screening for prediabetes and type 2 diabetes","volume":"326","author":"Davidson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib101","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/STROKEAHA.115.009128","article-title":"Is blood pressure control for stroke prevention the correct goal? The lost opportunity of preventing hypertension","volume":"46","author":"Howard","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.03.056_bib102","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002275","article-title":"Can antihypertensive treatment restore the risk of cardiovascular disease to ideal levels? The Coronary Artery Risk Development in Young Adults (CARDIA) study and the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"4","author":"Liu","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib103","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/S0002-9149(99)00355-0","article-title":"Insulin resistance and lipid metabolism","volume":"84","author":"Howard","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib104","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2021.12606","article-title":"Screening for prediabetes and type 2 diabetes","volume":"326","author":"Jin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib105","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/dme.13113","article-title":"Association between prediabetes and risk of chronic kidney disease: a systematic review and meta-analysis","volume":"33","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib106","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.jrn.2010.05.008","article-title":"Obesity and chronic kidney disease","volume":"20","author":"Kopple","year":"2010","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.jacc.2026.03.056_bib107","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacc.2014.09.077","article-title":"The natural course of healthy obesity over 20 years","volume":"65","author":"Bell","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib109","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1210\/jc.2018-01321","article-title":"Natural history of obesity subphenotypes: dynamic changes over two decades and prognosis in the Framingham Heart Study","volume":"104","author":"Echouffo-Tcheugui","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib110","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1210\/jc.2019-01338","article-title":"Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society\u2217 clinical practice guideline","volume":"104","author":"Rosenzweig","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib111","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2337\/dc21-1430","article-title":"Persistence of risk for type 2 diabetes after gestational diabetes mellitus","volume":"45","author":"Diaz-Santana","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib112","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib113","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib114","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib115","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib116","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tcm.2015.10.004","article-title":"Metabolic syndrome update","volume":"26","author":"Grundy","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib117","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc25-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib118","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib119","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib120","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40985-018-0094-7","article-title":"Screening for social determinants of health in clinical care: moving from the margins to the mainstream","volume":"39","author":"Andermann","year":"2018","journal-title":"Public Health Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib122","article-title":"Realizing the potential of social determinants data in EHR systems: a scoping review of approaches for screening, linkage, extraction, analysis, and interventions","volume":"8","author":"Li","year":"2024","journal-title":"J Clin Transl Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib123","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1017\/cts.2024.506","article-title":"Screening tools to address social determinants of health in the United States: a systematic review","volume":"8","author":"Neshan","year":"2024","journal-title":"J Clin Transl Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib124","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.48646","article-title":"Screening for social determinants of health during primary care and emergency department encounters","volume":"6","author":"Vilendrer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12872-025-04812-7","article-title":"Social determinants of health (SDOH) associated with the risk of all-cause mortality and life expectancy in US adults with cardiovascular-kidney-metabolic syndrome: a NHANES 2001-2018 cohort study","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2026.03.056_bib126","doi-asserted-by":"crossref","DOI":"10.31083\/RCM26580","article-title":"Social determinants of health in the development of cardiovascular-kidney-metabolic syndrome","volume":"26","author":"Cai","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib127","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45309","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages by social determinants of health","volume":"7","author":"Zhu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib128","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-065552","article-title":"Early childhood screening practices and barriers: a national survey of primary care pediatricians","volume":"154","author":"Coker","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2026.03.056_bib129","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1622","article-title":"Screening children for social determinants of health: a systematic review","volume":"144","author":"Sokol","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2026.03.056_bib130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOP.0000000000001189","article-title":"Addressing population health inequities: investing in the social determinants of health for children and families to advance child health equity","volume":"35","author":"Thornton","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jacc.2026.03.056_bib131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","article-title":"Social determinants of cardiovascular disease","volume":"130","author":"Powell-Wiley","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib132","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jpeds.2019.12.063","article-title":"Social determinants of cardiovascular health: early life adversity as a contributor to disparities in cardiovascular diseases","volume":"219","author":"Suglia","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2026.03.056_bib133","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026797","article-title":"Social determinants of cardiovascular health in US adolescents: National Health and Nutrition Examination Surveys 1999 to 2014","volume":"11","author":"Connolly","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib134","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2023.01.042","article-title":"Assessing and addressing social determinants of cardiovascular health: JACC state-of-the-art review","volume":"81","author":"Brandt","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1042\/CS20220304","article-title":"By what molecular mechanisms do social determinants impact cardiometabolic risk?","volume":"137","author":"Baumer","year":"2023","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacc.2026.03.056_bib136","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CN91WKDEDI","article-title":"Burden, access, and disparities in kidney disease","volume":"91","author":"Crews","year":"2019","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib137","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ackd.2014.11.003","article-title":"Social disadvantage: perpetual origin of kidney disease","volume":"22","author":"Crews","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib138","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib139","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dci20-0053","article-title":"Social determinants of health and diabetes: a scientific review","volume":"44","author":"Hill-Briggs","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034996","article-title":"Social risk profile and cardiovascular-kidney-metabolic syndrome in US adults","volume":"13","author":"Li","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib141","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.7326\/M23-0507","article-title":"Social, behavioral, and metabolic risk factors and racial disparities in cardiovascular disease mortality in U.S. adults: an observational study","volume":"176","author":"He","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib142","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amepre.2019.07.016","article-title":"Part II: a qualitative study of social risk screening acceptability in patients and caregivers","volume":"57","author":"Byhoff","year":"2019","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib143","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amepre.2019.07.010","article-title":"Part I: a quantitative study of social risk screening acceptability in patients and caregivers","volume":"57","author":"De Marchis","year":"2019","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib146","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30228","article-title":"Screening for health-related social needs and collaboration with external partners among US hospitals","volume":"6","author":"Ashe","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib147","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.amepre.2017.05.011","article-title":"A systematic review of interventions on patients' social and economic needs","volume":"53","author":"Gottlieb","year":"2017","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib148","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12875-024-02409-1","article-title":"Addressing food insecurity in rural primary care: a mixed-methods evaluation of barriers and facilitators","volume":"25","author":"Jordanova","year":"2024","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib153","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1370\/afm.2275","article-title":"Adoption of social determinants of health EHR tools by community health centers","volume":"16","author":"Gold","year":"2018","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib156","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.acap.2012.10.006","article-title":"Adverse childhood experiences: translating knowledge into identification of children at risk for poor outcomes","volume":"13","author":"Marie-Mitchell","year":"2013","journal-title":"Acad Pediatr"},{"key":"10.1016\/j.jacc.2026.03.056_bib159","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1542\/peds.2007-0398","article-title":"Improving the management of family psychosocial problems at low-income children's well-child care visits: the WE CARE Project","volume":"120","author":"Garg","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2026.03.056_bib160","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib161","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib162","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib163","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamacardio.2025.1865","article-title":"Performance of the American Heart Association's PREVENT equations among disaggregated racial and ethnic subgroups","volume":"10","author":"Yan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib164","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamacardio.2024.2912","article-title":"Tailoring risk prediction models to local populations","volume":"9","author":"Zinzuwadia","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib166","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002538","article-title":"Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data","volume":"15","author":"Karmali","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib167","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib168","author":"Khan","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.jacc.2026.03.056_bib169","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib170","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib171","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib172","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8584","article-title":"Cardiovascular risk associated with social determinants of health at individual and area levels","volume":"7","author":"Xia","year":"2024","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib173","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamacardio.2016.0991","article-title":"Risk of premature cardiovascular disease vs the number of premature cardiovascular events","volume":"1","author":"Sniderman","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib174","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCOUTCOMES.109.869727","article-title":"Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006","volume":"3","author":"Marma","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009351","article-title":"Distribution of 10-and 30-year predicted risks for heart failure in the US population: National Health and Nutrition Examination Surveys 2015 to 2018","volume":"15","author":"Hughes","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib176","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1001\/jama.2025.2868","article-title":"Discordance of 10- and 30-year predicted risk for cardiovascular disease in US adults","volume":"333","author":"Krishnan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib177","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jamacardio.2025.2427","article-title":"PREVENT risk age equations and population distribution in US adults","volume":"10","author":"Krishnan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib178","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45309","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages by social determinants of health","volume":"7","author":"Zhu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib179","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072112","article-title":"Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study","volume":"380","author":"Crump","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.03.056_bib180","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.2337\/dc21-0431","article-title":"Identification and predictors for cardiovascular disease risk equivalents among adults with diabetes mellitus","volume":"44","author":"Zhao","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib181","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamacardio.2022.4873","article-title":"Performance of cardiovascular risk prediction models among people living with HIV: a systematic review and meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib182","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib183","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib184","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib185","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib186","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib187","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib188","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2019.11.013","article-title":"Differential associations of chronic inflammatory diseases with incident heart failure","volume":"8","author":"Prasada","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib189","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.120.048026","article-title":"Number of social determinants of health and fatal and nonfatal incident coronary heart disease in the REGARDS study","volume":"143","author":"Safford","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib190","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib191","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027881","article-title":"Family history of modifiable risk factors and association with future cardiovascular disease","volume":"12","author":"Taylor","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib192","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamacardio.2021.1137","article-title":"State of the nation's cardiovascular health and targeting health equity in the United States: a narrative review","volume":"6","author":"Diaz","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib193","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib194","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jacc.2025.09.1509","article-title":"Age and sex-specific percentiles of 30-year cardiovascular disease risk based on the PREVENT equations","volume":"86","author":"Krishnan","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.jacc.2026.03.056_bib194a","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jacc.2018.07.042","article-title":"Positive psychological well-being and cardiovascular disease: JACC Health Promotion Series","volume":"72","author":"Kubzansky","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib195","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib196","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib197","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000134","article-title":"The role of primary care in achieving life's essential 8: a scientific statement from the American Heart Association","volume":"17","author":"Sterling","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib198","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib199","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamacardio.2019.3796","article-title":"Implications of specialist density for diabetes care in the United States","volume":"4","author":"Patel","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib200","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIR.0000000000001141","article-title":"Person-centered models for cardiovascular care: a review of the evidence: a scientific statement from the American Heart Association","volume":"148","author":"Rossi","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100630","article-title":"Second-year results from CINEMA: a novel, patient-centered, team-based intervention for patients with type 2 diabetes or prediabetes at high cardiovascular risk","volume":"17","author":"Neeland","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib202","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007682","article-title":"Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes","volume":"14","author":"Thomas","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib203","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.124.068962","article-title":"Effects of an intervention to improve evidence-based care for people with diabetes and cardiovascular disease across sex, race, and ethnicity subgroups: insights from the COORDINATE-Diabetes trial","volume":"150","author":"Tannu","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib204","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIR.0000000000000228","article-title":"Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association","volume":"132","author":"Havranek","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib205","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib206","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.pcd.2024.05.003","article-title":"The effects of multidisciplinary collaborative care on cardiovascular risk factors among patients with diabetes in primary care settings: a systematic review and meta-analysis","volume":"18","author":"Tu","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.jacc.2026.03.056_bib207","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/CIRCULATIONAHA.124.069494","article-title":"Randomized evaluation of a remote management program to improve guideline-directed medical therapy: the DRIVE trial","volume":"149","author":"Blood","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib208","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib209","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(22)02603-4","article-title":"Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial","volume":"401","author":"He","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib210","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007264","article-title":"Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care","volume":"13","author":"Rangaswami","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib211","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib212","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamainternmed.2024.0708","article-title":"Electronic health record population health management for chronic kidney disease care: a cluster randomized clinical trial","volume":"184","author":"Jhamb","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib213","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/nep.13070","article-title":"iConnect CKD - virtual medical consulting: a web-based chronic kidney disease, hypertension and diabetes integrated care program","volume":"23","author":"Katz","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jacc.2026.03.056_bib214","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.ajkd.2016.01.018","article-title":"Telehealth by an interprofessional team in patients with CKD: a randomized controlled trial","volume":"68","author":"Ishani","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib215","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.024482","article-title":"Lessons learned from a patient-centered, team-based intervention for patients with type 2 diabetes at high cardiovascular risk: year 1 results from the CINEMA program","volume":"11","author":"Neeland","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib216","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007682","article-title":"Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes","volume":"14","author":"Thomas","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib217","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1111\/dom.15691","article-title":"Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: proof-of-concept results from the DECIDE-CV clinical programme","volume":"26","author":"Marques","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib218","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.jacc.2016.03.528","article-title":"The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial","volume":"67","author":"Tsuyuki","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib219","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.123.010396","article-title":"Role of health care professionals in the success of blood pressure control interventions in patients with hypertension: a meta-analysis","volume":"17","author":"Mills","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib220","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1161\/HYPERTENSIONAHA.122.19816","article-title":"Comparing pharmacist-led telehealth care and clinic-based care for uncontrolled high blood pressure: the Hyperlink 3 pragmatic cluster-randomized trial","volume":"79","author":"Margolis","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2026.03.056_bib221","first-page":"449","article-title":"Development of a pharmacoeconomic model to demonstrate the effect of clinical pharmacist involvement in diabetes management","volume":"24","author":"Ourth","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacc.2026.03.056_bib222","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v15i3.6300","article-title":"Cost-effectiveness analysis of pharmacist-led diabetes management across primary care clinics","volume":"15","author":"King","year":"2024","journal-title":"Innov Pharm"},{"key":"10.1016\/j.jacc.2026.03.056_bib223","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41408","article-title":"Cost-effectiveness of pharmacist prescribing for managing hypertension in the United States","volume":"6","author":"Dixon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib224","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","article-title":"Social determinants of cardiovascular disease","volume":"130","author":"Powell-Wiley","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib225","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11606-018-4716-z","article-title":"Medically tailored meal delivery for diabetes patients with food insecurity: a randomized cross-over trial","volume":"34","author":"Berkowitz","year":"2019","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib226","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamainternmed.2016.7691","article-title":"Addressing unmet basic resource needs as part of chronic cardiometabolic disease management","volume":"177","author":"Berkowitz","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib227","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamainternmed.2013.14327","article-title":"Patient-centered community health worker intervention to improve posthospital outcomes: a randomized clinical trial","volume":"174","author":"Kangovi","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib228","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/sw\/swv016","article-title":"Impact of a social work care coordination intervention on hospital readmission: a randomized controlled trial","volume":"60","author":"Bronstein","year":"2015","journal-title":"Soc Work"},{"key":"10.1016\/j.jacc.2026.03.056_bib229","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib230","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib231","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"issue":"Suppl_1","key":"10.1016\/j.jacc.2026.03.056_bib232","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4147448","article-title":"The associations of cardiovascular-kidney-metabolic (CKM) syndrome stages with incident cardiovascular disease and cardiovascular mortality in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study","volume":"150","author":"Ozkan","year":"2024","journal-title":"Circulation"},{"issue":"Suppl_1","key":"10.1016\/j.jacc.2026.03.056_bib233","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4147884","article-title":"Transitions across stages of cardiovascular-kidney-metabolic syndrome and related implications for cardiovascular disease risk: the ARIC study","volume":"150","author":"Ozkan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib234","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.106.648642","article-title":"Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study","volume":"115","author":"Lloyd-Jones","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib235","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib236","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib237","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib238","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib239","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease risk and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib240","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib241","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib242","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib243","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.2337\/dc25-S003","article-title":"3. Prevention or delay of diabetes and associated comorbdities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib244","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31903","article-title":"Effect of a lifestyle intervention on cardiometabolic health among emerging adults: a randomized clinical trial","volume":"5","author":"LaRose","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib245","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jacc.2026.03.056_bib246","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000513664","article-title":"Effect of an intensive weight-loss lifestyle intervention on kidney function: a randomized controlled trial","volume":"52","author":"D\u00edaz-L\u00f3pez","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib247","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/obr.12264","article-title":"A systematic review of motivational interviewing for weight loss among adults in primary care","volume":"16","author":"Barnes","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib248","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib249","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib251","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jacc.2010.09.073","article-title":"The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals","volume":"57","author":"Kastorini","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib252","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.numecd.2009.04.015","article-title":"Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss","volume":"20","author":"Balducci","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib253","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib254","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13679-023-00495-3","article-title":"Obesity Stigma: Causes, Consequences, and Potential Solutions","volume":"12","author":"Westbury","year":"2023","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib256","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1177\/0956797615601103","article-title":"Weight discrimination and risk of mortality","volume":"26","author":"Sutin","year":"2015","journal-title":"Psychol Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib257","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ypmed.2014.02.001","article-title":"Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients","volume":"62","author":"Gudzune","year":"2014","journal-title":"Prev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib258","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/oby.23154","article-title":"Weight can't wait: a guide to discussing obesity and organizing treatment in the primary care setting","volume":"29","author":"Gallagher","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib259","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1108660","article-title":"Comparative effectiveness of weight-loss interventions in clinical practice","volume":"365","author":"Appel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib260","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jand.2022.03.014","article-title":"Weight management interventions provided by a dietitian for adults with overweight or obesity: an evidence analysis center systematic review and meta-analysis","volume":"123","author":"Morgan-Bathke","year":"2023","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jacc.2026.03.056_bib261","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014533","article-title":"Effect of interdisciplinary care on weight loss: a randomised controlled trial","volume":"7","author":"Tapsell","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib262","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.16595","article-title":"Effectiveness of combining antiobesity medication with an employer-based weight management program for treatment of obesity: a randomized clinical trial","volume":"4","author":"Pantalone","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib263","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.soard.2018.05.025","article-title":"ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg\/m2)","volume":"14","author":"Aminian","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib264","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASBMS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib266","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12889-017-4834-2","article-title":"Developing dimensions for a multicomponent multidisciplinary approach to obesity management: a qualitative study","volume":"17","author":"Cochrane","year":"2017","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacc.2026.03.056_bib267","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/bari.2022.0028","article-title":"Building a medical-surgical obesity center in an academic health system: lessons learned","volume":"18","author":"Davisson","year":"2023","journal-title":"Bariatric Surg Pract Patient Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib268","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000513664","article-title":"Effect of an intensive weight-loss lifestyle intervention on kidney function: a randomized controlled trial","volume":"52","author":"D\u00edaz-L\u00f3pez","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib269","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/obr.12264","article-title":"A systematic review of motivational interviewing for weight loss among adults in primary care","volume":"16","author":"Barnes","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib270","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jacc.2026.03.056_bib271","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31903","article-title":"Effect of a lifestyle intervention on cardiometabolic health among emerging adults: a randomized clinical trial","volume":"5","author":"LaRose","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib272","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.2024.0821","article-title":"An adaptive behavioral intervention for weight loss management: a randomized clinical trial","volume":"332","author":"Spring","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib273","doi-asserted-by":"crossref","DOI":"10.2196\/30416","article-title":"Long-term effectiveness of a smartphone app combined with a smart band on weight loss, physical activity, and caloric intake in a population with overweight and obesity (Evident 3): randomized controlled trial","volume":"24","author":"Lugones-Sanchez","year":"2022","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib274","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.12417","article-title":"Effect of a smartphone app on weight change and metabolic outcomes in Asian adults with type 2 diabetes: a randomized clinical trial","volume":"4","author":"Lim","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib275","article-title":"Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials","volume":"369","author":"Ge","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.03.056_bib276","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.2018.13022","article-title":"Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement","volume":"320","author":"Force","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib277","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am Psychol"},{"key":"10.1016\/j.jacc.2026.03.056_bib278","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib279","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib280","doi-asserted-by":"crossref","DOI":"10.1080\/17482631.2020.1862481","article-title":"Perspectives into the experience of successful, substantial long-term weight-loss maintenance: a systematic review","volume":"16","author":"Spreckley","year":"2021","journal-title":"Int J Qual Stud Health Well-being"},{"key":"10.1016\/j.jacc.2026.03.056_bib282","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2337\/ds17-0045","article-title":"Multidisciplinary team-based obesity treatment in patients with diabetes: current practices and the state of the science","volume":"30","author":"Foster","year":"2017","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jacc.2026.03.056_bib283","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamainternmed.2013.1232","article-title":"The future of obesity treatment: comment on integrating technology into standard weight loss treatment: a randomized controlled trial","volume":"173","author":"Rao","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib284","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12875-018-0785-7","article-title":"Five A's counseling in weight management of obese patients in primary care: a cluster-randomized controlled trial (INTERACT)","volume":"19","author":"Welzel","year":"2018","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib285","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib286","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib287","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib288","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib289","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1108660","article-title":"Comparative effectiveness of weight-loss interventions in clinical practice","volume":"365","author":"Appel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s13679-024-00552-5","article-title":"Behavioral lifestyle interventions for weight loss in overweight or obese patients with type 2 diabetes: a systematic review of the literature","volume":"13","author":"Gostoli","year":"2024","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib291","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/PPA.S103649","article-title":"Weight loss intervention adherence and factors promoting adherence: a meta-analysis","volume":"10","author":"Lemstra","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jacc.2026.03.056_bib292","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/nu12071977","article-title":"Effect of behavioral weight management interventions using lifestyle mHealth self-monitoring on weight loss: a systematic review and meta-analysis","volume":"12","author":"Cavero-Redondo","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2026.03.056_bib293","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/oby.23088","article-title":"Self-monitoring via digital health in weight loss Interventions: a systematic review among adults with overweight or obesity","volume":"29","author":"Patel","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib294","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.9609","article-title":"Web-based digital health interventions for weight loss and lifestyle habit changes in overweight and obese adults: systematic review and meta-analysis","volume":"21","author":"Beleigoli","year":"2019","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib295","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.2147\/DMSO.S384450","article-title":"Weight reduction interventions using digital health for employees with obesity: a systematic review","volume":"15","author":"Lee","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jacc.2026.03.056_bib296","article-title":"Mobile health (m-health) smartphone interventions for adolescents and adults with overweight or obesity","volume":"2","author":"Metzendorf","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib297","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fendo.2020.00412","article-title":"Mobile apps for weight management: a review of the latest evidence to inform practice","volume":"11","author":"Ghelani","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2026.03.056_bib299","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1161\/CIR.0000000000001146","article-title":"Popular dietary patterns: alignment with American Heart Association 2021 dietary guidance: a scientific statement from the American Heart Association","volume":"147","author":"Gardner","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib300","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1210\/clinem\/dgaa926","article-title":"Metabolic impact of intermittent fasting in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of interventional studies","volume":"106","author":"Borgundvaag","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib301","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.39558","article-title":"Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials","volume":"4","author":"Patikorn","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib302","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa2114833","article-title":"Calorie restriction with or without time-restricted eating in weight loss","volume":"386","author":"Liu","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib303","article-title":"Significant impact of the ketogenic diet on low-density lipoprotein cholesterol levels","volume":"12","author":"Salas Noain","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jacc.2026.03.056_bib304","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jand.2014.07.005","article-title":"Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons","volume":"114","author":"Johns","year":"2014","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jacc.2026.03.056_bib305","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001441","article-title":"Role of physical activity in obesity treatment and cardiometabolic health: a scientific statement from the American Heart Association","author":"Swift","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib306","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/oby.23905","article-title":"New insights in the mechanisms of weight-loss maintenance: summary from a Pennington symposium","volume":"31","author":"Flanagan","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib307","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13003","article-title":"Successful weight loss maintenance: a systematic review of weight control registries","volume":"21","author":"Paix\u00e3o","year":"2020","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib308","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pcad.2018.07.014","article-title":"The effects of exercise and physical activity on weight loss and maintenance","volume":"61","author":"Swift","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib309","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib310","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib311","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib312","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity: a systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jacc.2026.03.056_bib313","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"Gudzune","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib314","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13098-024-01371-3","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Salamah","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jacc.2026.03.056_bib316","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2026.03.056_bib317","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5)","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib318","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib319","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jacc.2026.03.056_bib320","author":"Atlas"},{"key":"10.1016\/j.jacc.2026.03.056_bib321","author":"Lin"},{"key":"10.1016\/j.jacc.2026.03.056_bib322","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib323","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib324","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib325","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib326","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: a systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib327","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib328","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2026.03.056_bib329","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","article-title":"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials","volume":"47","author":"de Mesquita","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jacc.2026.03.056_bib330","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib331","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13792","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Kommu","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib332","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib333","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib334","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib335","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacc.2026.03.056_bib336","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41591-025-03556-3","article-title":"Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial","volume":"31","author":"Tronieri","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib337","article-title":"Effects of phentermine \/ topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: a randomized, multicenter, double-blind study","volume":"9","author":"Bays","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.jacc.2026.03.056_bib338","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamasurg.2013.3654","article-title":"The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012","volume":"149","author":"Chang","year":"2014","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib339","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-018-3525-0","article-title":"Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding","volume":"29","author":"O'Brien","year":"2019","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib340","article-title":"Metabolic surgery in Asian patients with type 2 diabetes mellitus and body mass index less than 30kg\/m2: a systematic review","volume":"12","author":"Osorio Manyari","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.jacc.2026.03.056_bib341","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamasurg.2022.2229","article-title":"Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial","volume":"157","author":"Salminen","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib342","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","article-title":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis","volume":"43","author":"van Veldhuisen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib343","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib344","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jacc.2023.11.032","article-title":"Randomized trial of effect of bariatric surgery on blood pressure after 5 years","volume":"83","author":"Schiavon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib345","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib346","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib347","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s11695-024-07384-1","article-title":"Liraglutide for the treatment of weight regain after bariatric surgery: a systematic review and meta-analysis","volume":"34","author":"de Moraes","year":"2024","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib348","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s11695-024-07137-0","article-title":"Semaglutide and tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study","volume":"34","author":"Jamal","year":"2024","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib349","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib350","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s11695-014-1560-z","article-title":"Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery","volume":"25","author":"Cooper","year":"2015","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib351","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1038\/s41598-024-57724-5","article-title":"Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis","volume":"14","author":"Pipek","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib352","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15392","article-title":"Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality","volume":"7","author":"Dicker","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib353","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis","volume":"30","author":"Sarma","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib354","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib355","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.soard.2015.02.003","article-title":"Standardized outcomes reporting in metabolic and bariatric surgery","volume":"11","author":"Brethauer","year":"2015","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib356","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension: the GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension)","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib357","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S2213-8587(24)00396-6","article-title":"Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial","volume":"13","author":"Wagen Hauge","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib358","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.0087","article-title":"Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) bariatric study","volume":"155","author":"McTigue","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib359","author":"Ollendorf"},{"key":"10.1016\/j.jacc.2026.03.056_bib360","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48317","article-title":"Estimated cost-effectiveness of medical therapy, sleeve gastrectomy, and gastric bypass in patients with severe obesity and type 2 diabetes","volume":"5","author":"Lauren","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib361","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamasurg.2025.4385","article-title":"Costs of cutting weight-an economic evaluation of GLP-1 agonists vs gastric bypass","volume":"160","author":"Luo","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib362","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M17-2786","article-title":"Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study","volume":"169","author":"Arterburn","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib363","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sjostrom","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib364","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/jama.2018.14433","article-title":"Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes","volume":"320","author":"King","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib365","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/clinem\/dgaa702","article-title":"Approach to the patient: management of the post-bariatric surgery patient with weight regain","volume":"106","author":"Istfan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib366","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1007\/s11695-022-06211-9","article-title":"The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis","volume":"32","author":"Lautenbach","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib367","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamainternmed.2013.1232","article-title":"The future of obesity treatment: comment on integrating technology into standard weight loss treatment: a randomized controlled trial","volume":"173","author":"Rao","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib368","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13098-021-00650-7","article-title":"The utility of diagnostic tests in the detection and prediction of glucose intolerance in the early and late postpartum period in women after gestational diabetes: a longitudinal cohort study","volume":"13","author":"Quansah","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jacc.2026.03.056_bib369","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2022.100609","article-title":"Postpartum glucose intolerance following early gestational diabetes mellitus","volume":"4","author":"Champion","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"10.1016\/j.jacc.2026.03.056_bib370","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.tjog.2023.01.005","article-title":"Comparing the detection rate of postpartum diabetes in early and 4-12 week postpartum screening tests in women with gestational diabetes mellitus: a systematic review and meta-analysis","volume":"62","author":"Mousavi","year":"2023","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib371","first-page":"200","article-title":"Prevalence of glucose intolerance in early postpartum and its associated factors among women with history of gestational diabetes mellitus","volume":"18","author":"Bahari","year":"2022","journal-title":"Malays J Med Health Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib372","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2023.101107","article-title":"Effect of prenatal counseling on postpartum follow-up and contraceptive use in women with gestational diabetes mellitus: a randomized controlled trial","volume":"5","author":"Phaloprakarn","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"10.1016\/j.jacc.2026.03.056_bib373","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1210\/jc.2014-3761","article-title":"The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up","volume":"100","author":"Aroda","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib374","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/AOG.0000000000000420","article-title":"A web-based lifestyle intervention for women with recent gestational diabetes mellitus: a randomized controlled trial","volume":"124","author":"Nicklas","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib375","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1210\/jc.2017-02654","article-title":"Postnatal lifestyle intervention for overweight women with previous gestational diabetes: a randomized controlled trial","volume":"103","author":"Holmes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib376","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/HYPERTENSIONAHA.115.06747","article-title":"Healthful dietary patterns and the risk of hypertension among women with a history of gestational diabetes mellitus: a prospective cohort study","volume":"67","author":"Li","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2026.03.056_bib377","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00125-019-4840-2","article-title":"Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis","volume":"62","author":"Kramer","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib378","volume":"4","author":"Zhang","year":"2024","journal-title":"AJOG Glob Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib379","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc20-S014","article-title":"14: Management of diabetes in pregnancy: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib380","series-title":"Diabetes in pregnancy: management from preconception to the postnatal period","year":"2020"},{"key":"10.1016\/j.jacc.2026.03.056_bib381","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2337\/dc23-2149","article-title":"Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus","volume":"47","author":"Durnwald","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib382","doi-asserted-by":"crossref","first-page":"439.e1","DOI":"10.1016\/j.ajog.2020.05.036","article-title":"Two-day postpartum compared with 4- to 12-week postpartum glucose tolerance testing for women with gestational diabetes","volume":"223","author":"Werner","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib383","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.123.322001","article-title":"Pregnancy as an early cardiovascular moment: peripartum cardiovascular health","volume":"132","author":"Khan","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib384","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1161\/CIR.0000000000001212","article-title":"Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: a scientific statement from the American Heart Association","volume":"149","author":"Lewey","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib385","article-title":"Perinatal care in primary care for cardiovascular risk reduction","volume":"25","author":"Macdonald","year":"2025","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jacc.2026.03.056_bib386","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1210\/jc.2008-0772","article-title":"Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions","volume":"93","author":"Ratner","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib387","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/obr.13689","article-title":"Effect of dietary and physical activity behavioral interventions on reducing postpartum weight retention among women with recent gestational diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"He","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib388","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/jdi.14220","article-title":"Postpartum life interventions to prevent type 2 diabetes in women with gestational diabetes: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2024","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jacc.2026.03.056_bib389","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13006-019-0238-5","article-title":"The effect of breastfeeding on postpartum glucose tolerance and lipid profiles in women with gestational diabetes mellitus","volume":"14","author":"Shub","year":"2019","journal-title":"Int Breastfeed J"},{"key":"10.1016\/j.jacc.2026.03.056_bib390","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1374682","article-title":"Impact of breastfeeding on risk of glucose intolerance in early postpartum after gestational diabetes","volume":"15","author":"Vanlaer","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2026.03.056_bib391","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13006-024-00632-1","article-title":"Lactation duration and development of type 2 diabetes and metabolic syndrome in postpartum women with recent gestational diabetes mellitus","volume":"19","author":"Suthasmalee","year":"2024","journal-title":"Int Breastfeed J"},{"key":"10.1016\/j.jacc.2026.03.056_bib392","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020462","article-title":"Improving cardiometabolic and mental health in women with gestational diabetes mellitus and their offspring: study protocol for MySweetHeart Trial, a randomised controlled trial","volume":"8","author":"Horsch","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib393","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/M18-1605","article-title":"Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program outcomes study","volume":"170","author":"Apolzan","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib394","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11892-019-1200-z","article-title":"Public health approaches to type 2 diabetes prevention: the US National Diabetes Prevention Program and beyond","volume":"19","author":"Gruss","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib395","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/nu15071613","article-title":"The association of specific dietary patterns with cardiometabolic outcomes in women with a history of gestational diabetes mellitus: a scoping review","volume":"15","author":"O'Hara","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2026.03.056_bib396","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archinternmed.2012.3747","article-title":"Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus","volume":"172","author":"Tobias","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib397","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2026.03.056_bib398","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2007.10.016","article-title":"Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes","volume":"199","author":"Xiang","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2026.03.056_bib399","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib400","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib401","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ejcn.2014.243","article-title":"Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis","volume":"69","author":"Huo","year":"2015","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacc.2026.03.056_bib402","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/dc10-0676","article-title":"Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial","volume":"34","author":"Azadbakht","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib403","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib404","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib405","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib406","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib407","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib408","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","article-title":"Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study","volume":"61","author":"Oellgaard","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib409","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib410","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 diabetes: microvascular and cardiovascular outcomes","volume":"387","author":"Group","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib411","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib412","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib413","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib414","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"Neuen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib415","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108921","article-title":"GLP-1 receptor agonists for cardiovascular outcomes with and without metformin: a systematic review and meta-analysis of cardiovascular outcomes trials","volume":"177","author":"Tsapas","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib416","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/ds19-0031","article-title":"Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes","volume":"33","author":"Anderson","year":"2020","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jacc.2026.03.056_bib417","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib418","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib419","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib420","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib421","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2026.03.056_bib422","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib423","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease risk and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib424","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2008.10.008","volume":"53","author":"Skyler","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib425","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib426","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib427","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib428","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib429","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20132025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study","volume":"22","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2026.03.056_bib431","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib432","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.jacc.2018.04.027","article-title":"Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus","volume":"71","author":"Liu","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib433","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s11695-020-05068-0","article-title":"All-cause mortality of patients with and without diabetes following bariatric surgery: comparison to non-surgical matched patients","volume":"31","author":"Dicker","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib434","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/jama.2018.14619","article-title":"Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity","volume":"320","author":"Fisher","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib435","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.soard.2019.04.029","article-title":"Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes","volume":"15","author":"Billeter","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib436","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib437","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tcm.2015.10.004","article-title":"Metabolic syndrome update","volume":"26","author":"Grundy","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib438","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"G\u00e6de","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib439","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib440","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib441","author":"Khan","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.jacc.2026.03.056_bib442","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","article-title":"A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes","volume":"20","author":"Yoshida","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib443","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dom.14268","article-title":"Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States","volume":"23","author":"Reifsnider","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib444","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1016\/j.xphs.2019.04.022","article-title":"Quantifying the value of orally delivered biologic therapies: a cost-effectiveness analysis of oral semaglutide","volume":"108","author":"Abramson","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib445","first-page":"455","article-title":"Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes","volume":"27","author":"Guzauskas","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacc.2026.03.056_bib446","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.7326\/M21-2941","article-title":"First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study","volume":"175","author":"Choi","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib447","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/M23-1492","article-title":"Cost-effectiveness of newer pharmacologic treatments in adults with type 2 diabetes: a systematic review of cost-effectiveness studies for the American College of Physicians","volume":"177","author":"Schousboe","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib448","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jacc.2026.03.056_bib449","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2337\/dc24-2241","article-title":"Cost-effectiveness of semaglutide compared with other glucose-lowering medications in treating type 2 diabetes: a comprehensive systematic review and meta-analysis","volume":"48","author":"Liu","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib450","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib452","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib453","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib454","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-vowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib455","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2026.03.056_bib456","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2020.07.005","article-title":"Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial)","volume":"132","author":"Nelson","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib457","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib458","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.5551\/jat.64625","article-title":"Associations between the serum triglyceride level and kidney outcome in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry study","volume":"31","author":"Seki","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacc.2026.03.056_bib459","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000522388","article-title":"Association of serum triglycerides and renal outcomes among 1.6 million US Veterans","volume":"146","author":"Soohoo","year":"2022","journal-title":"Nephron"},{"key":"10.1016\/j.jacc.2026.03.056_bib460","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib461","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib462","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.2337\/dc08-0423","article-title":"Metabolic syndrome and incident diabetes: current state of the evidence","volume":"31","author":"Ford","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib463","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib464","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib465","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib466","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib467","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib468","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib469","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib470","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12882-022-02763-1","article-title":"The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials","volume":"23","author":"Alsalemi","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib471","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib472","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib473","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc21-2034","article-title":"Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib474","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib475","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib476","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib477","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib478","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1097\/MS9.0000000000001180","article-title":"Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-Analysis","volume":"85","author":"Yasmin","year":"2023","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib479","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib480","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib481","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib482","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib483","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib484","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib485","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib486","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010827","article-title":"Atorvastatin has a dose-dependent beneficial effect on kidney function and associated cardiovascular outcomes: post hoc analysis of 6 double-blind randomized controlled trials","volume":"8","author":"Vogt","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib487","author":"Khan","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.jacc.2026.03.056_bib488","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib489","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib490","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib491","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.03.056_bib492","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.303","volume":"5","author":"Seidu","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib493","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib494","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2021.09.014","article-title":"Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial","volume":"79","author":"Reifsnider","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib495","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","article-title":"Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease","volume":"37","author":"Tisdale","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib496","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib497","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib498","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib499","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/dom.15997","article-title":"Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States","volume":"27","author":"Zheng","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib501","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib502","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib503","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib504","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib505","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib506","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib507","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.008995","article-title":"Guideline-directed medical therapy attainment and outcomes in dialysis-requiring versus nondialysis chronic kidney disease in the ISCHEMIA-CKD trial","volume":"15","author":"Mathew","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib508","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib509","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2337\/dc19-0936","article-title":"The long-term effects of metformin on patients with type 2 diabetic kidney disease","volume":"43","author":"Kwon","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib510","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib511","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib512","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076444","article-title":"Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials","volume":"14","author":"Bansal","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib513","article-title":"Finerenone in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use","volume":"65","author":"Caramori","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib514","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jcmg.2020.12.024","article-title":"Coronary artery calcium for the allocation of GLP-1RA for primary prevention of atherosclerotic cardiovascular disease","volume":"14","author":"Cainzos-Achirica","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.03.056_bib515","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcmg.2021.10.017","article-title":"CAC for risk stratification among individuals with hypertriglyceridemia free of clinical atherosclerotic cardiovascular disease","volume":"15","author":"Cainzos-Achirica","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.03.056_bib516","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCULATIONAHA.116.025471","article-title":"Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy","volume":"135","author":"McEvoy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib517","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib518","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","article-title":"Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"2","author":"Malik","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib519","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/ndt\/gfac194","article-title":"Association of coronary artery calcium with adverse cardiovascular outcomes and death in patients with chronic kidney disease: results from the KNOW-CKD","volume":"38","author":"Jung","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.03.056_bib520","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2014020173","article-title":"Subclinical atherosclerosis measures for cardiovascular prediction in CKD","volume":"26","author":"Matsushita","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib521","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2010.461","article-title":"Coronary artery calcium score and risk classification for coronary heart disease prediction","volume":"303","author":"Polonsky","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib522","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejvs.2004.11.013","article-title":"Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes: results from the population study 'Men born in 1914' from Malmo, Sweden","volume":"29","author":"Ogren","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib523","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2009.11.075","article-title":"Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study","volume":"55","author":"Nambi","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib524","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.2014.14681","article-title":"Nonobstructive coronary artery disease and risk of myocardial infarction","volume":"312","author":"Maddox","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib525","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003528","article-title":"Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients","volume":"9","author":"Valenti","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.03.056_bib526","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ahj.2009.08.007","article-title":"Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"158","author":"Budoff","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib527","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib528","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib529","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2012.14312","article-title":"Lifetime risk and years lived free of total cardiovascular disease","volume":"308","author":"Wilkins","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib530","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","article-title":"Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease","volume":"2","author":"Chen","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib531","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7440","article-title":"Association of coronary artery calcium with long-term, cause-specific mortality among young adults","volume":"2","author":"Miedema","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib532","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2026.03.056_bib533","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jcmg.2021.11.011","article-title":"The utility of coronary artery calcium for guiding treatment with preventive pharmacotherapy: opportunities and nuances","volume":"15","author":"Virani","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.03.056_bib534","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jacr.2018.04.029","article-title":"Managing incidental findings on thoracic CT: mediastinal and cardiovascular findings. a white paper of the ACR Incidental Findings Committee","volume":"15","author":"Munden","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib535","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2023.06.040","article-title":"Association of coronary artery calcium detected by routine ungated CT imaging with cardiovascular outcomes","volume":"82","author":"Peng","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib536","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcct.2018.03.008","article-title":"CAC-DRS: coronary artery calcium data and reporting system. an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT)","volume":"12","author":"Hecht","year":"2018","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2026.03.056_bib537","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcct.2017.02.010","article-title":"Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography","volume":"11","author":"Hecht","year":"2017","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2026.03.056_bib538","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.121.054117","article-title":"One-year committed exercise training reverses abnormal left ventricular myocardial stiffness in patients with stage B heart failure with preserved ejection fraction","volume":"144","author":"Hieda","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib539","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2024.11.004","article-title":"Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: Look AHEAD cardiac biomarker ancillary study","volume":"85","author":"Patel","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib540","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib541","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib542","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib543","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib544","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib545","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib546","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib547","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib548","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics \u2014 an updated 2024 report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib549","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2023.04.007","article-title":"Effect of 2022 ACC\/AHA\/HFSA criteria on stages of heart failure in a pooled community cohort","volume":"81","author":"Mohebi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib550","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1161\/CIR.0000000000001307","article-title":"Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association","volume":"151","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib551","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1161\/01.CIR.88.5.2277","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators","volume":"88","author":"Konstam","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib552","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0735-1097(96)00489-5","article-title":"Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study","volume":"29","author":"Vantrimpont","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib553","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib554","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib555","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.jacc.2018.08.1029","article-title":"2018 AHA\/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Stout","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib556","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib557","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib558","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib559","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/jama.2020.21749","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement","volume":"324","author":"Force","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib560","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.2022.10951","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: US preventive services task force recommendation statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib561","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide\u2013based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib562","article-title":"Cardiac biomarkers, intensive lifestyle intervention, and heart failure subtypes in diabetes: Look AHEAD cardiac biomarker ancillary study","author":"Chunawala","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib563","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jchf.2021.04.003","article-title":"Physical activity, subclinical myocardial injury, and risk of heart failure subtypes in Black adults","volume":"9","author":"Patel","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib564","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","article-title":"Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial","volume":"148","author":"Januzzi","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib565","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.cardfail.2024.03.010","article-title":"Natriuretic peptides and prognosis in patients with type 2 diabetes mellitus and high risk for cardiovascular events","volume":"30","author":"Khan","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib566","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacc.2021.11.027","article-title":"Stress cardiac biomarkers, cardiovascular and renal outcomes, and response to canagliflozin","volume":"79","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib567","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/jamacardio.2023.0019","article-title":"Association of cardiac biomarkers with major adverse cardiovascular events in high-risk patients with diabetes: a secondary analysis of the DECLARE-TIMI 58 trial","volume":"8","author":"Zelniker","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib568","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12933-022-01618-1","article-title":"Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial","volume":"21","author":"Nesti","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2026.03.056_bib569","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib570","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-017-0546-2","article-title":"Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study","volume":"16","author":"Yamada","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2026.03.056_bib571","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00392-023-02164-w","article-title":"Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial","volume":"112","author":"Prochaska","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib572","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib573","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib574","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.124.072889","article-title":"The association between tirzepatide versus insulin glargine and NT-proBNP levels in people with type 2 diabetes with or at elevated risk for cardiovascular disease: post hoc analyses of SURPASS 4","volume":"151","author":"Sattar","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib575","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib576","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ehf2.14962","article-title":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes","volume":"12","author":"Filippatos","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib577","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib578","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib579","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2026.03.056_bib580","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib581","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib582","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib583","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib584","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.03.056_bib585","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib586","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib587","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.159.10.1104","article-title":"Clustering of metabolic factors and coronary heart disease","volume":"159","author":"Wilson","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib588","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib589","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib590","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.03.056_bib591","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib592","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib593","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(11)61344-5","article-title":"Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial","volume":"378","author":"Jebb","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib594","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2018.7777","article-title":"Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"LeBlanc","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib595","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-023-01182-3","article-title":"Risk stratification and treatment of obesity for primary and secondary prevention of cardiovascular disease","volume":"26","author":"Ostrominski","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib596","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOL.0000000000000044","article-title":"Dietary patterns, Mediterranean diet, and cardiovascular disease","volume":"25","author":"Martinez-Gonzalez","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2026.03.056_bib597","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib598","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib599","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2337\/ds17-0045","article-title":"Multidisciplinary team-based obesity treatment in patients with diabetes: current practices and the state of the science","volume":"30","author":"Foster","year":"2017","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jacc.2026.03.056_bib600","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.120.048585","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with previous myocardial infarction and severe obesity: a nationwide cohort study","volume":"143","author":"N\u00e4slund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib601","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","article-title":"Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study","volume":"143","author":"Doumouras","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib602","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib603","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacc.2026.03.056_bib604","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCULATIONAHA.120.051328","article-title":"Effects of a 2-year primary care lifestyle intervention on cardiometabolic risk factors: a cluster-randomized trial","volume":"143","author":"H\u00f6chsmann","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib605","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030132","article-title":"Effect of intensive lifestyle intervention on cardiovascular risk factors: analysis from the perspective of long-term variability","volume":"13","author":"He","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib606","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/01939459231209735","article-title":"Behavioral weight loss interventions for overweight and obese cardiac rehabilitation patients: a systematic review","volume":"45","author":"Barnason","year":"2023","journal-title":"West J Nurs Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib607","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108389","article-title":"Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases","volume":"37","author":"Handelsman","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacc.2026.03.056_bib608","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib609","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib610","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2026.03.056_bib611","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJMoa2007448","article-title":"Weight loss in underserved patients: a cluster-randomized trial","volume":"383","author":"Katzmarzyk","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib612","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib613","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib614","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2025.5243","article-title":"Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in US adults","author":"Hennessy","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib615","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.soard.2018.05.025","article-title":"ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg\/m2)","volume":"14","author":"Aminian","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib616","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1001\/jama.2013.5835","article-title":"Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial","volume":"309","author":"Ikramuddin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib617","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jama.299.3.316","article-title":"Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial","volume":"299","author":"Dixon","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib618","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib619","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib620","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s11695-019-04363-9","article-title":"Laparoscopic sleeve gastrectomy carries a lower perioperative mortality including sudden cardiac death over Roux-en-Y gastric bypass in patients with a prior cardiac history: an MBSAQIP analysis","volume":"30","author":"Foster","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-053117-123246","article-title":"Bariatric surgery as a long-term treatment for type 2 diabetes\/metabolic syndrome","volume":"71","author":"Hanipah","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib622","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ejcn.2014.243","article-title":"Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis","volume":"69","author":"Huo","year":"2015","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jacc.2026.03.056_bib623","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/dc10-0676","article-title":"Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial","volume":"34","author":"Azadbakht","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib624","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.03.056_bib625","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in persons with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib626","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1741826710393197","article-title":"Effect of combined aerobic and resistance training versus aerobic training alone in individuals with coronary artery disease: a meta-analysis","volume":"19","author":"Marzolini","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib627","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.111.177071","article-title":"Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials","volume":"58","author":"Cornelissen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2026.03.056_bib628","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.754794","article-title":"Efficacy and safety of resistance training for coronary heart disease rehabilitation: a systematic review of randomized controlled trials","volume":"8","author":"Fan","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib629","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12966-020-01007-5","article-title":"Dose-response relationship between physical activity and mortality in adults with noncommunicable diseases: a systematic review and meta-analysis of prospective observational studies","volume":"17","author":"Geidl","year":"2020","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jacc.2026.03.056_bib630","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12966-020-00978-9","article-title":"Systematic review of the prospective association of daily step counts with risk of mortality, cardiovascular disease, and dysglycemia","volume":"17","author":"Hall","year":"2020","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jacc.2026.03.056_bib631","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106593","article-title":"Lifestyle interventions to reduce sedentary behaviour in clinical populations: a systematic review and meta-analysis of different strategies and effects on cardiometabolic health","volume":"148","author":"Nieste","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib632","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/dom.13016","article-title":"Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese high-risk adults: a randomized crossover trial","volume":"19","author":"McCarthy","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib633","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/gerona\/gly252","article-title":"Metabolic effects of breaking prolonged sitting with standing or light walking in older South Asians and White Europeans: a randomized acute study","volume":"75","author":"Yates","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib634","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.03.056_bib635","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib636","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib637","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib638","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib639","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib640","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib641","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib642","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib643","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib644","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib645","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib646","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib647","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib648","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib649","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE)","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib650","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib651","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib652","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib653","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.jacc.2018.04.027","article-title":"Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus","volume":"71","author":"Liu","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib654","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib655","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdi.12625","article-title":"Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis","volume":"8","author":"Cai","year":"2017","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jacc.2026.03.056_bib656","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib657","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib658","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib659","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib660","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib661","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib662","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib663","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib664","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ejhf.633","article-title":"Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes","volume":"19","author":"Fitchett","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib665","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib666","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib667","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib668","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib669","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib670","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib671","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib672","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2215\/CJN.0000000000000568","article-title":"Sodium-glucose cotransporter 2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis","volume":"20","author":"Spiazzi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib673","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib674","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib675","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib676","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib677","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib678","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib679","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib680","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dom.14268","article-title":"Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States","volume":"23","author":"Reifsnider","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib681","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","article-title":"A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes","volume":"20","author":"Yoshida","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacc.2026.03.056_bib683","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.5586","article-title":"Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jacc.2026.03.056_bib684","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib685","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12020-019-02175-6","article-title":"The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis","volume":"67","author":"Guo","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2026.03.056_bib686","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib687","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib688","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(24)00183-9","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?","volume":"12","author":"Escobar Cervantes","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib689","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib690","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib691","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.03.056_bib692","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.03.056_bib693","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib694","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib695","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurheartj\/ehac825","article-title":"Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study","volume":"44","author":"Mark","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib696","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib697","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib698","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib699","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib700","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib701","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib702","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib703","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib704","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib705","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib706","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib707","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib708","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2024.06.002","article-title":"2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"84","author":"Writing","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib709","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib710","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib711","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib712","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib713","article-title":"A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction","volume":"16","author":"Brubaker","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib714","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022930","article-title":"Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction","volume":"10","author":"El Hajj","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib715","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1527-5299.2005.03827.x","article-title":"Effect of orlistat in obese patients with heart failure: a pilot study","volume":"11","author":"Beck-da-Silva","year":"2005","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib716","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JCN.0b013e31819846b9","article-title":"Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study","volume":"24","author":"Evangelista","year":"2009","journal-title":"J Cardiovasc Nurs"},{"key":"10.1016\/j.jacc.2026.03.056_bib717","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2165-7904.1000118","article-title":"Lifestyle modification with diet and exercise in obese patients with heart failure: a pilot study","volume":"2","author":"Pritchett","year":"2012","journal-title":"J Obes Weight Loss Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib718","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ehf2.13213","article-title":"High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro-HEART trial","volume":"8","author":"Evangelista","year":"2021","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.jacc.2026.03.056_bib719","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cardfail.2020.12.011","article-title":"Bariatric surgery in patients with obesity and ventricular assist devices considered for heart transplantation: systematic review and individual participant data meta-analysis","volume":"27","author":"daSilva-deAbreu","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib720","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib721","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jchf.2024.06.006","article-title":"Obesity and weight loss strategies for patients with heart failure","volume":"12","author":"Vest","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib722","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cardfail.2019.03.007","article-title":"Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee","volume":"25","author":"Vest","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib723","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","article-title":"Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study","volume":"143","author":"Doumouras","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib724","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019323","volume":"10","author":"Hoskuldsdottir","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib725","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib726","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10741-024-10410-0","article-title":"Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS","volume":"29","author":"Harrington","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib727","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib728","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib729","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","article-title":"Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study","volume":"58","author":"Edelmann","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib730","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2026141","article-title":"Physical rehabilitation for older patients hospitalized for heart failure","volume":"385","author":"Kitzman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib731","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.2020.26812","article-title":"Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"325","author":"Mueller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib732","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib733","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.amjcard.2011.07.051","article-title":"Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure","volume":"108","author":"Horwich","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib734","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib735","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jchf.2024.10.018","article-title":"Antiobesity medications in patients with heart failure: a clinical protocol and preliminary single-center experience","volume":"13","author":"Hussani","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib736","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2020.09.007","article-title":"In-hospital outcomes after bariatric surgery in patients with heart failure","volume":"230","author":"Blumer","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib737","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jchf.2024.04.006","article-title":"Obesity, challenges, and weight-loss strategies for patients with ventricular assist devices","volume":"12","author":"daSilva-deAbreu","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib738","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib739","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib740","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib741","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib742","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib743","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib744","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib745","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib746","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-010-1906-6","article-title":"Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study","volume":"53","author":"Andersson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2026.03.056_bib747","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib748","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.124.072889","article-title":"The association between tirzepatide versus insulin glargine and NT-proBNP levels in people with type 2 diabetes with or at elevated risk for cardiovascular disease: post hoc analyses of SURPASS 4","volume":"151","author":"Sattar","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib749","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib750","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib751","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib752","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib754","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","article-title":"Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"8","author":"Cohen","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib755","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamainternmed.2022.5010","article-title":"Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction","volume":"182","author":"Zheng","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib756","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib757","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib758","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib759","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cardfail.2024.10.448","article-title":"GLP-1 receptor agonist in nonobese patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction","volume":"31","author":"Khadke","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib760","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/heartjnl-2016-309806","article-title":"Contemporary risk estimates of three HbA(1c) variables in relation to heart failure following diagnosis of type 2 diabetes","volume":"103","author":"Skrtic","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2026.03.056_bib761","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.1210\/jc.2013-3325","article-title":"HbA1c and heart failure risk among diabetic patients","volume":"99","author":"Zhao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib762","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12872-016-0275-6","article-title":"Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes","volume":"16","author":"Blecker","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2026.03.056_bib763","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ejhf.455","article-title":"Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study","volume":"18","author":"Elder","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib764","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2005.10.008","article-title":"An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure","volume":"151","author":"Eshaghian","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib765","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2009.04.049","article-title":"Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes","volume":"54","author":"Aguilar","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib766","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib767","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/CIRCHEARTFAILURE.110.952556","article-title":"Metformin use and mortality in ambulatory patients with diabetes and heart failure","volume":"4","author":"Aguilar","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib768","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib769","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc25-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib770","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib771","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib772","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2024.03.392","article-title":"Effects of sacubitril\/valsartan across the spectrum of renal impairment in patients with heart failure","volume":"83","author":"Chatur","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib773","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib774","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib775","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.hlc.2023.12.013","article-title":"Efficacy of guideline-directed medical therapy in heart failure patients with and without chronic kidney disease: a meta-analysis of 63,677 patients","volume":"33","author":"Clark","year":"2024","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2026.03.056_bib776","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2349135","article-title":"The role of sacubitril\/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis","volume":"46","author":"Yang","year":"2024","journal-title":"Ren Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib777","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib778","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib779","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib780","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/ehjcvp\/pvae003","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis","volume":"10","author":"Theodorakopoulou","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.03.056_bib781","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib782","article-title":"Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3\/4 CKD: a meta-analysis","volume":"17","author":"Li","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2026.03.056_bib783","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib784","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib785","first-page":"672","article-title":"Patiromer-facilitated renin-angiotensin-aldosterone system inhibitor utilization in patients with heart failure with or without comorbid chronic kidney disease: subgroup analysis of DIAMOND randomized trial","volume":"55","author":"Weir","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib786","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejim.2023.08.022","article-title":"Novel potassium binders to optimize RAASi therapy in heart failure: a systematic review and meta-analysis","volume":"119","author":"Paolillo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib787","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib788","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib789","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib791","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000132","article-title":"2024 Update to the 2020 ACC\/AHA clinical performance and quality measures for adults with heart failure: a report of the American Heart Association\/American College of Cardiology Joint Committee on Performance Measures","volume":"17","author":"Kittleson","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib792","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-024-02941-8","article-title":"A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials","volume":"30","author":"Kondo","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib793","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacc.2026.03.056_bib794","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.109.853648","article-title":"Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure","volume":"120","author":"Anand","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib795","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib796","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2026.03.056_bib797","doi-asserted-by":"crossref","DOI":"10.1177\/1470320319882656","article-title":"Effects of dual blockade in heart failure and renal dysfunction: systematic review and meta-analysis","volume":"20","author":"Silva","year":"2019","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jacc.2026.03.056_bib798","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/ehf2.13338","article-title":"Corrigendum","volume":"8","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib799","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib800","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib801","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchf.2024.08.022","article-title":"Angiotensin receptor neprilysin inhibition and cardiovascular outcomes across the kidney function spectrum: the PARAGON-HF trial","volume":"13","author":"Mc Causland","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib802","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib803","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib804","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib805","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/M16-0057","article-title":"Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction","volume":"165","author":"Sandhu","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib806","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib807","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib809","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2023.19129","article-title":"The Inflation Reduction Act and access to high-cost cardiovascular therapies","volume":"330","author":"Kazi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib810","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","article-title":"Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"8","author":"Cohen","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib811","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamainternmed.2022.5010","article-title":"Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction","volume":"182","author":"Zheng","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib812","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib813","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1814","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib814","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib815","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2026.03.056_bib816","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.cardfail.2022.04.003","article-title":"Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus patiromer","volume":"28","author":"Zhuo","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2026.03.056_bib817","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib818","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijcard.2016.12.029","article-title":"Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis","volume":"231","author":"Neefs","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib819","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib820","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2215\/CJN.0000000693","article-title":"Efficacy and safety of SGLT-2 inhibitors in patients with and without advanced CKD: a systematic review and meta-analysis","volume":"20","author":"Elenjickal","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib821","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib822","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib823","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/diseases12010014","article-title":"Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis","volume":"12","author":"Krisanapan","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.jacc.2026.03.056_bib824","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib825","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/M23-3236","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials","volume":"177","author":"Ku","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib826","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib827","series-title":"2024 USRDS annual data report: epidemiology of kidney disease in the United States\u2014mortality","year":"2024"},{"key":"10.1016\/j.jacc.2026.03.056_bib828","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309773","article-title":"Frequent hemodialysis versus standard hemodialysis for people with kidney failure: Systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Natale","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2026.03.056_bib829","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/nep.12435","article-title":"Statins for end-stage kidney disease treated with dialysis","volume":"20","author":"Webster","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jacc.2026.03.056_bib830","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib831","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib832","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.03.056_bib833","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib834","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib835","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib836","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/HEP.0000000000000842","article-title":"Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline","volume":"81","author":"Patel","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib837","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jacc.2026.03.056_bib838","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib839","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib840","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib841","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib842","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib843","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib844","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib845","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib846","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib847","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib848","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apt.18451","article-title":"Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease","volume":"61","author":"Owrangi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib849","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib850","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/HEP.0000000000000286","article-title":"The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study","volume":"77","author":"Ahmed","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib851","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2026.03.056_bib852","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.03.056_bib853","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib854","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib855","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2024.10.017","article-title":"Successful example of implementing screening of liver fibrosis in specialist diabetes care","volume":"4","author":"Tajudin","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.jacc.2026.03.056_bib856","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.03.056_bib857","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib858","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41591-024-03480-y","article-title":"Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Aminian","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib859","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.03.056_bib860","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib861","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib862","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib863","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","article-title":"The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population","volume":"51","author":"Jinjuvadia","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jacc.2026.03.056_bib864","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2026.03.056_bib865","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.03.056_bib866","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib867","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib868","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib869","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib870","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.03.056_bib871","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.03.056_bib872","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib873","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib874","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib875","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/MEG.0000000000002158","article-title":"Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease","volume":"33","author":"Sinn","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib876","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib877","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1753-0407.13086","article-title":"Effect of exercise on hepatic steatosis: are benefits seen without dietary intervention? a systematic review and meta-analysis","volume":"13","author":"Baker","year":"2021","journal-title":"J Diabetes"},{"key":"10.1016\/j.jacc.2026.03.056_bib878","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014918","article-title":"A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease","volume":"98","author":"Abdelbasset","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2026.03.056_bib879","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.24958","article-title":"Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list","volume":"24","author":"Duarte-Rojo","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jacc.2026.03.056_bib880","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cgh.2020.07.023","article-title":"Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib881","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cgh.2021.12.043","article-title":"Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease","volume":"21","author":"Chun","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib882","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.17308","article-title":"Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Henry","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib883","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.31158","article-title":"Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease","volume":"72","author":"Kim","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.03.056_bib884","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.3390\/jcm12175603","article-title":"Aerobic and muscle-strengthening physical activity, television viewing, and nonalcoholic fatty liver disease: the CARDIA study","volume":"12","author":"McDonough","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib885","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib886","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib887","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes","volume":"20","author":"Simon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib888","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2023.06.004","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jacc.2026.03.056_bib889","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1373\/jalm.2018.027359","article-title":"Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis","volume":"3","author":"Day","year":"2019","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib890","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3324\/haematol.10828","article-title":"Venous thromboembolism: a manifestation of the metabolic syndrome","volume":"92","author":"Ay","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2026.03.056_bib891","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1513\/AnnalsATS.201907-518OC","article-title":"Metabolic syndrome increases risk of venous thromboembolism recurrence after acute pulmonary embolism","volume":"17","author":"Stewart","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jacc.2026.03.056_bib892","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1538-7836.2008.03234.x","article-title":"Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Troms\u00f8 study","volume":"7","author":"Borch","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib893","doi-asserted-by":"crossref","first-page":"909","DOI":"10.29271\/jcpsp.2022.07.909","article-title":"Idiopathic venous thromboembolism and metabolic syndrome: a meta-analysis","volume":"32","author":"Abuduhalike","year":"2022","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jacc.2026.03.056_bib894","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/ATVBAHA.114.304085","article-title":"Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysis","volume":"34","author":"Ageno","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.03.056_bib895","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/met.2010.0117","article-title":"The metabolic syndrome and its individual components: its association with venous thromboembolism in a mediterranean population","volume":"9","author":"Vay\u00e1","year":"2011","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jacc.2026.03.056_bib896","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2009.03295.x","article-title":"Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology","volume":"7","author":"Steffen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib897","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035329","article-title":"Association between diabetes and venous thromboembolism: a systematic review and meta-analysis","volume":"102","author":"Ding","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2026.03.056_bib898","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13018-024-04624-z","article-title":"Influence of diabetes on the risk of deep vein thrombosis of patients after total knee arthroplasty: a meta-analysis","volume":"19","author":"An","year":"2024","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib899","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110190","article-title":"Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males","volume":"194","author":"Deischinger","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib900","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.thromres.2010.12.006","article-title":"Prevalence of arterial and venous thromboembolic events in diabetic patients with and without the metabolic syndrome: a cross sectional study","volume":"127","author":"Dentali","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib901","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14452","article-title":"Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism","volume":"38","author":"Hinton","year":"2021","journal-title":"Diabet Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib902","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jdiacomp.2016.06.019","article-title":"Blood glucose on admission and mortality in patients with venous thromboembolism","volume":"31","author":"Akirov","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacc.2026.03.056_bib903","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejim.2015.10.001","article-title":"Is diabetes mellitus a risk factor for venous thromboembolism? a systematic review and meta-analysis of case-control and cohort studies","volume":"28","author":"Gariani","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib904","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.diabres.2015.10.019","article-title":"Diabetes mellitus and venous thromboembolism: a systematic review and meta-analysis","volume":"111","author":"Bell","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib905","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2215\/CJN.0000000000000352","article-title":"Association of eGFR and albuminuria with venous thromboembolism","volume":"19","author":"Zheng","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib906","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1053\/j.ajkd.2017.07.003","article-title":"Risk of venous thromboembolism in patients by albuminuria and estimated GFR","volume":"70","author":"Massicotte-Azarniouch","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib907","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2010.04048.x","article-title":"Chronic kidney disease stages 1-3 increase the risk of venous thrombosis","volume":"8","author":"Ocak","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib908","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/ndt\/gfq179","article-title":"Chronic kidney disease and venous thromboembolism: a prospective study","volume":"25","author":"Folsom","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.03.056_bib909","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22886","article-title":"Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib910","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib911","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib912","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.ajkd.2020.02.446","article-title":"Risk of cardiovascular events and mortality among elderly patients with reduced GFR receiving direct oral anticoagulants","volume":"76","author":"Ashley","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.03.056_bib913","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.3390\/jcm13133784","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in obese patients (BMI \u2265 30 kg\/m2) with atrial fibrillation or venous thromboembolism: an updated systematic review and meta-analysis","volume":"13","author":"Karakasis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib914","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cpt.2131","article-title":"Thromboembolic and hemorrhagic outcomes in the direct oral anticoagulant trials across the spectrum of kidney function","volume":"109","author":"Limdi","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib915","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.11.005","article-title":"2026 AHA\/ACC\/ACCP\/ACEP\/CHEST\/SCAI\/SHM\/SIR\/SVM\/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"Creager","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib916","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11239-023-02774-1","article-title":"DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network","volume":"55","author":"Martin","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2026.03.056_bib917","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/07853890.2014.982064","article-title":"Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials","volume":"47","author":"Di Minno","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib918","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11239-020-02179-4","article-title":"Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis","volume":"51","author":"Elshafei","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2026.03.056_bib919","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/a-1588-9155","article-title":"Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis","volume":"122","author":"Wang","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib920","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous thromboembolism: a meta-analysis","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2026.03.056_bib921","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight: a sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib922","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"Cohen","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacc.2026.03.056_bib923","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jtha.2024.08.009","article-title":"Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients","volume":"22","author":"Dobry","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib924","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-9560-12-25","article-title":"Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment","volume":"12","author":"Bauersachs","year":"2014","journal-title":"Thromb J"},{"key":"10.1016\/j.jacc.2026.03.056_bib925","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib926","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib927","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1160\/TH16-03-0244","article-title":"Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: an analysis of the randomised, double-blind HOKUSAI VTE trial","volume":"116","author":"Verhamme","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.03.056_bib928","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.11.036","article-title":"Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis","volume":"198","author":"Alhousani","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib929","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jacc.2026.03.056_bib930","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1060028020967635","article-title":"Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes","volume":"55","author":"Cheung","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2026.03.056_bib931","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","article-title":"A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease","volume":"35","author":"Parker","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib932","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.14021021","article-title":"Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis","volume":"17","author":"Wetmore","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib933","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: a national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib934","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2023.06.027","article-title":"Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: a systematic review and meta-analysis","volume":"229","author":"Almajdi","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2026.03.056_bib935","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jcph.1838","article-title":"The pharmacology, efficacy, and safety of rivaroxaban in renally impaired patient populations","volume":"61","author":"Ashton","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.03.056_bib936","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.5664\/jcsm.6064","article-title":"Quality measure for screening for adult obstructive sleep apnea by primary care physicians","volume":"12","author":"Aurora","year":"2016","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib937","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2022.20304","article-title":"Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib938","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2024.06.008","article-title":"Adverse cardiovascular outcomes in patients with obstructive sleep apnea and obesity: metabolic surgery vs usual care","volume":"84","author":"Aminian","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib939","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","article-title":"A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study","volume":"169","author":"Foster","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib940","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib941","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.284.23.3015","article-title":"Longitudinal study of moderate weight change and sleep-disordered breathing","volume":"284","author":"Peppard","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib942","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/aje\/kws342","article-title":"Increased prevalence of sleep-disordered breathing in adults","volume":"177","author":"Peppard","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib943","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.hrtlng.2025.01.005","article-title":"Rising cardiovascular mortality among obstructive sleep apnea patients: United States epidemiological trends (1999-2019)","volume":"70","author":"Ali","year":"2025","journal-title":"Heart Lung"},{"key":"10.1016\/j.jacc.2026.03.056_bib944","series-title":"Diagnosis and Treatment of Obstructive Sleep Apnea in Adults","author":"Balk","year":"2011"},{"key":"10.1016\/j.jacc.2026.03.056_bib945","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.wjorl.2015.08.001","article-title":"Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome","volume":"1","author":"Knauert","year":"2015","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.jacc.2026.03.056_bib946","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1001\/jama.2022.18357","article-title":"Screening for obstructive sleep apnea in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"328","author":"Feltner","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib947","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib948","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1164\/rccm.201703-0603OC","article-title":"Effect of obstructive sleep apnea treatment on renal function in patients with cardiovascular disease","volume":"196","author":"Loffler","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib949","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1164\/rccm.201601-0088OC","article-title":"Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea: the RICCADSA randomized controlled trial","volume":"194","author":"Peker","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib950","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib951","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.smrv.2016.10.004","article-title":"Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth Sleepiness Scale in detecting obstructive sleep apnea: a bivariate meta-analysis","volume":"36","author":"Chiu","year":"2017","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.jacc.2026.03.056_bib952","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5664\/jcsm.6506","article-title":"Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Kapur","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib953","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2022.01.047","article-title":"Long-term cardiovascular outcomes after bariatric surgery in the Medicare population","volume":"79","author":"Mentias","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib954","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.orcp.2024.06.003","article-title":"Cardio-metabolic health effects of CPAP treatment for sleep apnoea during weight loss: a randomised controlled pilot trial","volume":"18","author":"Hoyos","year":"2024","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib955","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/AOG.0000000000000591","article-title":"Risk of adverse pregnancy outcomes by prepregnancy body mass index: a population-based study to inform prepregnancy weight loss counseling","volume":"125","author":"Schummers","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib956","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ajog.2018.02.003","article-title":"Maternal and neonatal outcomes after bariatric surgery; a systematic review and meta-analysis: do the benefits outweigh the risks?","volume":"218","author":"Kwong","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib957","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/nu10060698","article-title":"Associations of diet and physical activity with risk for gestational diabetes mellitus: a systematic review and meta-analysis","volume":"10","author":"Mijatovic-Vukas","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2026.03.056_bib958","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archinternmed.2012.3747","article-title":"Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus","volume":"172","author":"Tobias","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib959","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc20-S014","article-title":"14. Management of diabetes in pregnancy: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib960","doi-asserted-by":"crossref","first-page":"99.e1","DOI":"10.1016\/j.ajog.2020.07.027","article-title":"Weight loss prior to pregnancy and subsequent gestational weight gain: PREPARE, a randomized clinical trial","volume":"224","author":"LeBlanc","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib961","doi-asserted-by":"crossref","first-page":"158.e1","DOI":"10.1016\/j.ajog.2023.01.037","article-title":"Randomized controlled trial of prepregnancy lifestyle intervention to reduce recurrence of gestational diabetes mellitus","volume":"229","author":"Phelan","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib962","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.2337\/dc10-1113","article-title":"Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control","volume":"33","author":"Murphy","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib963","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.09250914","article-title":"A systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy","volume":"10","author":"Zhang","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib964","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12882-019-1560-2","article-title":"Clinical practice guideline on pregnancy and renal disease","volume":"20","author":"Wiles","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib965","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/AOG.0000000000003256","article-title":"Chronic kidney disease and pregnancy","volume":"133","author":"Hui","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib966","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1161\/CIR.0000000000000961","article-title":"Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association","volume":"143","author":"Parikh","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib967","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2023.102435","article-title":"Pregnancy-associated cardiovascular risks and postpartum care; an opportunity for interventions aiming at health preservation and disease prevention","volume":"92","author":"Wallin","year":"2024","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib968","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/bmjqs-2018-007837","article-title":"Comparing standard office-based follow-up with text-based remote monitoring in the management of postpartum hypertension: a randomised clinical trial","volume":"27","author":"Hirshberg","year":"2018","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jacc.2026.03.056_bib969","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jamacardio.2022.0553","article-title":"Effectiveness of a text-based gamification intervention to improve physical activity among postpartum individuals with hypertensive disorders of pregnancy: a randomized clinical trial","volume":"7","author":"Lewey","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib970","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajog.2022.12.309","article-title":"Mobilizing the fourth trimester to improve population health: interventions for postpartum transitions of care","volume":"229","author":"Phillips","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib971","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/AOG.0000000000005237","article-title":"Electronic reminder to transition care after hypertensive disorders of pregnancy: a randomized controlled trial","volume":"142","author":"Triebwasser","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib972","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1161\/CIR.0000000000001124","article-title":"Optimizing prepregnancy cardiovascular health to improve outcomes in pregnant and postpartum individuals and offspring: a scientific statement from the American Heart Association","volume":"147","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib973","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025050","article-title":"Temporal trends in adverse pregnancy outcomes in birthing individuals aged 15 to 44 years in the United States, 2007 to 2019","volume":"11","author":"Freaney","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib974","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2393-10-63","article-title":"Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis","volume":"10","author":"Wahabi","year":"2010","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.jacc.2026.03.056_bib975","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078282","article-title":"Promoting Reproductive Planning And Readiness in Diabetes (PREPARED) Study protocol: a clinic-randomised controlled trial testing a technology-based strategy to promote preconception care for women with type 2 diabetes","volume":"13","author":"Bailey","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.03.056_bib976","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae084","article-title":"Pre-gestational counselling for women living with CKD: starting from the bright side","volume":"17","author":"Da Silva","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacc.2026.03.056_bib977","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003497","article-title":"Preeclampsia and future cardiovascular health: a systematic review and meta-analysis","volume":"10","author":"Wu","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2026.03.056_bib978","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108625","article-title":"The absolute and relative risk of type 2 diabetes after gestational diabetes: a systematic review and meta-analysis of 129 studies","volume":"171","author":"Dennison","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib979","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10654-013-9762-6","article-title":"Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis","volume":"28","author":"Brown","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib980","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s12020-016-1075-6","article-title":"Hypertensive disorders during pregnancy and risk of type 2 diabetes in later life: a systematic review and meta-analysis","volume":"55","author":"Wang","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2026.03.056_bib981","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.ogx.0000721620.59805.5c","article-title":"Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis","volume":"75","author":"Vounzoulaki","year":"2020","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.jacc.2026.03.056_bib982","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib983","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020717","article-title":"Trends in prepregnancy obesity and association with adverse pregnancy outcomes in the United States, 2013 to 2018","volume":"10","author":"Wang","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib984","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/EDE.0b013e318225c960","article-title":"Preconception cardiovascular risk factors and pregnancy outcome","volume":"22","author":"Harville","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.jacc.2026.03.056_bib985","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1210\/jc.2015-3904","article-title":"Prepregnancy adverse lipid profile and subsequent risk of gestational diabetes","volume":"101","author":"Han","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib986","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejogrb.2014.07.015","article-title":"Maternal and neonatal outcomes in women undergoing bariatric surgery: a systematic review and meta-analysis","volume":"181","author":"Galazis","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jacc.2026.03.056_bib987","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3390\/nu10070914","article-title":"Dietary patterns prior to pregnancy and associations with pregnancy complications","volume":"10","author":"Jarman","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2026.03.056_bib988","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(18)30311-8","article-title":"Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health","volume":"391","author":"Stephenson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib989","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2337\/dc10-1368","article-title":"Physical activity before and during pregnancy and risk of gestational diabetes mellitus: a meta-analysis","volume":"34","author":"Tobias","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib990","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2201295","article-title":"Treatment for mild chronic hypertension during pregnancy","volume":"386","author":"Tita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib991","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1097\/AOG.0000000000002960","article-title":"ACOG practice bulletin no. 201: pregestational diabetes mellitus","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib992","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2021.02.033","article-title":"Team-based care of women with cardiovascular disease from pre-conception through pregnancy and postpartum: JACC Focus Seminar 1\/5","volume":"77","author":"Davis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib993","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1681\/ASN.2014050459","article-title":"Risk of adverse pregnancy outcomes in women with CKD","volume":"26","author":"Piccoli","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib994","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1161\/CIR.0000000000001212","article-title":"Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: a scientific statement from the American Heart Association","volume":"149","author":"Lewey","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib995","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1161\/CIR.0000000000000582","volume":"137","author":"Brown","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.03.056_bib996","first-page":"245","article-title":"Excess pregnancy weight gain and long-term obesity: one decade later","volume":"100","author":"Rooney","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib997","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.123.22231","article-title":"Blood pressure trajectories through the first year postpartum in overweight or obese individuals following a hypertensive disorder of pregnancy","volume":"81","author":"Hauspurg","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2026.03.056_bib998","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/HYPERTENSIONAHA.122.19275","article-title":"De novo postpartum hypertension: incidence and risk factors at a safety-net hospital","volume":"80","author":"Parker","year":"2023","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2026.03.056_bib999","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijgo.14540","article-title":"Hypertensive disorders of pregnancy and long-term cardiovascular health: FIGO best practice advice","volume":"160","author":"Poon","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jacc.2026.03.056_bib1000","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1001","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1002","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1003","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1004","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1097\/AOG.0000000000002633","article-title":"736: optimizing postpartum care","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1005","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/jamacardio.2021.4391","article-title":"Interventions to mitigate risk of cardiovascular disease after adverse pregnancy outcomes: a review","volume":"7","author":"Jowell","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1006","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11606-013-2744-2","article-title":"Utilization of primary and obstetric care after medically complicated pregnancies: an analysis of medical claims data","volume":"29","author":"Bennett","year":"2014","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1007","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/ANNALS-24-03849","article-title":"Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide: a randomized clinical trial","volume":"178","author":"Billings","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1008","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib1009","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1010","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib1011","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.03.056_bib1012","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib1013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M16-2855","article-title":"Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial","volume":"167","author":"Beck","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1014","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2337\/dc22-1699","article-title":"Optimization of albuminuria-lowering treatment in diabetes by crossover rotation to four different drug classes: a randomized crossover trial","volume":"46","author":"Curovic","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib1015","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib1016","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1017","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2215\/CJN.0000000000000550","article-title":"Baseline, early changes, and residual albuminuria: post hoc analysis of a randomized clinical trial of dapagliflozin in chronic kidney disease","volume":"19","author":"van Mil","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1018","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1019","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib1020","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib1021","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1022","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1023","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1024","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib1025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1026","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/03007995.2024.2322072","article-title":"Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide","volume":"40","author":"Urva","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2026.03.056_bib1027","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib1028","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc25-S006","article-title":"Glycemic goals and hypoglycemia: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib1029","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1373\/clinchem.2010.148841","article-title":"Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care","volume":"57","author":"Little","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2026.03.056_bib1030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1032","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2026.03.056_bib1033","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"Neuen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib1034","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108921","article-title":"GLP-1 receptor agonists for cardiovascular outcomes with and without metformin: a systematic review and meta-analysis of cardiovascular outcomes trials","volume":"177","author":"Tsapas","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2026.03.056_bib1035","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.03.056_bib1036","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib1037","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/dom.12802","article-title":"Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes","volume":"19","author":"Nauck","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.03.056_bib1038","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.056_bib1039","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1041","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1042","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1043","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1044","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1046","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2026.03.056_bib1047","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.03.056_bib1048","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib1049","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.03.056_bib1050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2026.03.056_bib1051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020237","article-title":"Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes","volume":"10","author":"Xie","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.03.056_bib1052","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726059000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726059000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:39:09Z","timestamp":1786567149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726059000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":1037,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0735109726059000"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.056","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}